Exclusive Online Content
Appili Therapeutics Enters Commercial Agreement With Saptalis Pharmaceuticals
Appili Therapeutics Inc. recently announced it has entered into a commercialization agreement with Saptalis Pharmaceuticals LLC on ATI-1501, Appili’s liquid suspension reformulation of the…..
Biogen Announces Positive Phase 2 Study Results
Biogen Inc. recently announced positive top-line results from the Phase 2 LILAC study evaluating the efficacy and safety of BIIB059, a fully humanized….
OWP Pharmaceuticals Announces Second IND Approval & Patent Application for First-Ever Liquid Oral Suspension Formulation
OWP Pharmaceuticals, Inc. recently announced today that it has received Investigational New Drug (IND) approval from the US FDA, and has submitted for US patent protection, for the first-ever liquid formulation of….
Encouraging Results of Pilot Study Testing Bionic Pancreas
Beta Bionics, Inc., a medical technology company developing and aiming to commercialize the world’s first fully automated bionic pancreas, recently announced its bionic pancreas glucose control algorithms that use lifelong autonomous learning were deployed in….
PPD Expands Special Patient Capabilities in Early Development Research
PPD, Inc. has expanded its early development research services by adding significant neuroscience and ethno-bridging expertise, broadening its capabilities to provide increased access to…..
Recipharm Announces Commercial Manufacturing to Support Drug Launch Following FDA Approval
Recipharm, the contract development and manufacturing organisation (CDMO), recently announced ongoing large-scale commercial manufacturing of RedHill Biopharma’s drug, Talicia (omeprazole magnesium,…..
Catalent to Supply BeiGene's BTK Inhibitor BRUKINSAT
Catalent recently announced it had entered into a long-term commercial supply agreement with BeiGene, Ltd., a biopharmaceutical company focused on developing….
Excision BioTherapeutics Presents Data to Support HIV Cure Using CRISPR Gene Editing Technology
On November 20 at the 6th Annual Personalized Nanomedicine Symposium, researchers working with Excision BioTherapeutics, a gene therapy company focusing on curing viral infectious diseases, delivered two oral presentations to review the multiple years of…
Appili Therapeutics Acquires Clinical-Stage Program From FUJIFILM Toyama Chemical
Appili Therapeutics Inc. recently announced it has signed an agreement with FUJIFILM Toyama Chemical Co., Ltd. to acquire and develop the novel……
Protalix BioTherapeutics & Chiesi Farmaceutici Announce Successful Pre-BLA Meeting
Protalix BioTherapeutics, Inc. and its development and commercialization partner, Chiesi Farmaceutici S.p.A. recently announced that they have completed a successful Type B Pre-Biologics License Application (BLA) meeting with the US FDA regarding….
Seelos Therapeutics Receives FDA Fast Track Designation for Intranasal Drug
Seelos Therapeutics, Inc. recently announced the US FDA has granted Fast Track designation to its new, investigational intranasal racemic ketamine program, SLS-002, for the treatment of…..
Cytel Acquires MTEK Sciences, Further Expanding Advanced Real-World Analytics Capabilities
Cytel Inc. recently announced that it has acquired MTEK Sciences to further expand its advanced real-world analytics (RWA) capabilities….
Vetter’s US Site Offers Clinical Manufacturing for Successful Drug Development of Injectables
Pharma and biotech companies, both large and small, have high expectations for their new molecules they have in development. Even the smallest of details can impact the eventual success or failure of their product…..
Aptar Acquires Noble International, a Leader in Drug Delivery Training Devices & Patient Onboarding
AptarGroup, Inc. recently announced it has acquired Noble International, a leader in drug delivery training devices and patient onboarding. This acquisition furthers Aptar’s strategy to broaden……
Flexion Announces Clearance of NDA for Gene Therapy Candidate
Flexion Therapeutics, Inc. recently announced clearance of the company’s Investigational New Drug (IND) application for FX201 in knee osteoarthritis.
Cycle Pharmaceuticals & Catalent Partner to Develop Treatments for Rare Diseases
Cycle Pharmaceuticals Ltd. has recently signed an agreement with Catalent, Inc. to develop innovative formulations targeting rare disease patients.
Ashland Launches New Excipient Solutions for Improved Drug Delivery
Ashland recently announced the launch of three new pharmaceutical solutions, Plasdone S630 Ultra, Benecel XR and XRF, and Viatel bioresorbable polymers. Ashland is expanding its portfolio to meet formulators’ growing needs….
Amarantus Enters Into Agreement to License Diverse Therapeutics Portfolio to CBD-Focused Emerald Organic Products
Amarantus will receive Emerald Preferred Stock to be valued at a minimum of $100 million in 2022, and up to double digit royalties (in addition to pass-through royalties and milestones) in exchange for worldwide, exclusive development and commercial rights to….
Sustainability is Everyone’s Obligation
Acting with social responsibility is far more than the very important role of environment protection, it also includes overall sustainability and acting in a manner that…..
Nanotechnology World Association is Launched by Solid Group of Founding Members
This new global nanotechnology association will bolster the necessary links between research and industries and facilitate the adoption and commercialization of…….
